Assetmark Inc. boosted its position in Agilent Technologies, Inc. (NYSE:A - Free Report) by 60.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,561 shares of the medical research company's stock after buying an additional 38,808 shares during the period. Assetmark Inc.'s holdings in Agilent Technologies were worth $15,228,000 at the end of the most recent quarter.
Other institutional investors have also added to or reduced their stakes in the company. Crewe Advisors LLC grew its holdings in shares of Agilent Technologies by 114.8% during the second quarter. Crewe Advisors LLC now owns 189 shares of the medical research company's stock valued at $25,000 after buying an additional 101 shares during the last quarter. Livelsberger Financial Advisory acquired a new position in Agilent Technologies during the 3rd quarter valued at about $28,000. Ridgewood Investments LLC bought a new stake in Agilent Technologies during the 2nd quarter worth approximately $29,000. Fortitude Family Office LLC increased its holdings in Agilent Technologies by 68.3% during the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company's stock worth $35,000 after purchasing an additional 95 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in shares of Agilent Technologies in the second quarter worth approximately $39,000. 87.42% of the stock is owned by institutional investors and hedge funds.
A has been the subject of several recent research reports. Evercore ISI upped their price target on Agilent Technologies from $135.00 to $145.00 and gave the stock an "in-line" rating in a report on Tuesday, October 1st. Barclays upped their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an "underweight" rating in a research note on Tuesday, October 15th. UBS Group raised their price target on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a "neutral" rating in a research report on Thursday, August 22nd. TD Cowen upped their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a "buy" rating in a research report on Thursday, August 22nd. Finally, Wells Fargo & Company started coverage on Agilent Technologies in a report on Tuesday, August 27th. They issued an "overweight" rating and a $157.00 target price for the company. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $144.36.
Read Our Latest Research Report on A
NYSE A opened at $136.68 on Monday. The company's 50 day moving average is $139.46 and its 200-day moving average is $138.20. The company has a quick ratio of 1.37, a current ratio of 1.78 and a debt-to-equity ratio of 0.36. Agilent Technologies, Inc. has a 12-month low of $104.09 and a 12-month high of $155.35. The firm has a market cap of $39.27 billion, a P/E ratio of 28.36, a price-to-earnings-growth ratio of 6.06 and a beta of 1.07.
Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, beating analysts' consensus estimates of $1.26 by $0.06. The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.43 EPS. Sell-side analysts predict that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were paid a dividend of $0.236 per share. The ex-dividend date was Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.69%. Agilent Technologies's dividend payout ratio (DPR) is currently 19.50%.
In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the transaction, the chief executive officer now directly owns 24,118 shares of the company's stock, valued at approximately $3,497,110. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,995 shares of company stock worth $1,739,510 in the last ninety days. 0.33% of the stock is owned by insiders.
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.